No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Lisata Therapeutics Reports Q1 2025 Financial Results
Lisata Therapeutics GAAP EPS of -$0.55 Misses by $0.02
Lisata Outlines Data-rich Year Ahead With Multiple Clinical Milestones for Certepetide
Express News | Lisata Therapeutics Inc: Cash Runway Extending Into Q3 of 2026 With No Debt
Lisata Eyes Key Trial Milestones in 2025 as Certepetide Development Gains Momentum | NASDAQ:LSTA
Lisata Therapeutics | 10-Q: Quarterly report